a Department of Medicine , Copenhagen University Hospital Gentofte , Copenhagen , Denmark.
b Center for Innovative Therapy , University of California , San Diego , CA , USA.
Expert Rev Clin Immunol. 2016 Oct;12(10):1027-36. doi: 10.1080/1744666X.2016.1224658. Epub 2016 Aug 25.
Secukinumab (Cosentyx) is an interleukin-17A (IL-17A) inhibitor administered subcutaneously. Through 2016, it had received approval in a number of countries, including the USA, Japan and in the EU for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
This review addresses the mechanism of action, efficacy and safety of secukinumab observed in clinical studies of patients with PsA. Data from recent studies of secukinumab in psoriasis, PsA and AS are included. Expert commentary: Secukinumab appears to be effective in improving various aspects of PsA, including improvements in psoriatic skin, enthesitis and dactylitis, as well as inhibition of the radiographic progression of peripheral arthritis. Secukinumab was in general well tolerated; the most common adverse events were nasopharyngitis, headache, and upper respiratory tract infection.
司库奇尤单抗（可善挺）是一种皮下注射用白细胞介素-17A（IL-17A）抑制剂。截至 2016 年，该药已在多个国家获得批准，包括美国、日本和欧盟，用于治疗斑块状银屑病、银屑病关节炎（PsA）和强直性脊柱炎（AS）。
本篇综述讨论了司库奇尤单抗在治疗银屑病关节炎患者的临床研究中观察到的作用机制、疗效和安全性。纳入了来自最近关于司库奇尤单抗治疗银屑病、PsA 和 AS 的研究数据。
司库奇尤单抗似乎能有效改善银屑病关节炎的多个方面，包括改善银屑病皮肤、附着点炎和指（趾）炎，并抑制外周关节炎的放射学进展。司库奇尤单抗总体耐受性良好；最常见的不良事件是鼻咽炎、头痛和上呼吸道感染。
